Metabolomic Association and Risk Prediction With Heart Failure in Older Adults
Heart Failure
Right Ventricular Failure
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial
Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial
Rapid and Intensive Guideline-Directed Medical Therapy for Heart Failure: 5 Core Principles
Evaluation and Management of Kidney Dysfunction in Advanced Heart Failure: A Scientific Statement From the American Heart Association
Hospital Heart Failure Medical Therapy Score and Associated Clinical Outcomes and Costs
Guideline‐Directed Medical Therapy After Hospitalization for Acute Heart Failure: Insights From the CONNECT‐HF
Optimal Medical Therapy for Heart Failure and Integrated Care in Patients With Atrial Fibrillation: A Report From the ESC‐EHRA EORP Atrial Fibrillation Long‐Term General Registry
Withdrawal of Guideline-Directed Medical Therapy in Patients With Heart Failure and Improved Ejection Fraction
Economic burden of cardiovascular disease in the United Kingdom
Real‐life implementation of guideline‐recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of <span style="font-variant:small-caps;">TITRATE</span> ‐ <span style="font-variant:small-caps;">HF</span>
Timing of Cardiac Resynchronization Therapy Following Stable Medical Therapy in Patients With Heart Failure
